AstraZeneca inhaler lags GSK drug in lung disease trial


A new AstraZeneca inhaler for chronic lung disease has proved worse than a rival GlaxoSmithKline product in a clinical trial, a result AstraZeneca said was inconsistent with earlier findings. FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014.



from Biotech News